CK Wang, MD, explains that Black women face higher rates of late-stage breast and ovarian cancer diagnoses, demonstrating the ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

Nearly half of sequencing data labeled as endometriosis lacks true disease representation, highlighting the urgent need for more diverse and accurate tissue sampling to advance research in this ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

kDepartment of Gynecology and Obstetrics, Hospital Anregiomed Ansbach, Ansbach, Germany lDepartment of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany mViDia Christliche ...

as the healthy tissue surrounding a solid cancer is often critical for survival but expresses similar proteins to the tumors themselves. In contrast, natural T-cells with T-cell receptors (TCRs ...

New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer.

"This work adds a critical piece to the puzzle of why ovarian cancer is so aggressive and has such poor outcomes. While the immune system is naturally equipped to detect and destroy cancer cells ...

Boston-based Ve­rastem On­col­o­gy on Thurs­day won ac­cel­er­at­ed ap­proval from the FDA for Avmap­ki Fakzyn­ja as a sec­ond-line treat­ment for adult pa­tients with KRAS-mu­tat ...

A woman's chances of surviving ovarian cancer at least five years after diagnosis come down to the toss of a coin: just 49% will reach that milestone, making it one of the most lethal reproductive ...

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...